DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer

Clinical Cancer Research

Volumn 16, Issue 23, 2010, Pages 5796-5804

  Alexander, Brian M ^a,b   Sprott, Kam ^c   Farrow, D Allan ^c   Wang, XiaoZhe ^c   D'Andrea, Alan D ^a   Schnitt, Stuart J ^a   Collins, Laura C ^a   Weaver, David T ^c   Garber, Judy E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^c On Q ity   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DEOXYRIBONUCLEOPROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER RECURRENCE; DNA REPAIR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK;

ADULT; BREAST NEOPLASMS; CARCINOMA; COHORT STUDIES; DNA REPAIR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650326983     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0292     Document Type: Article

References (56)

1. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235-44.
2. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofaniili M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
3. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008;14:8010-8.
4. Turner N, Tutt A, Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev 2004;4:814-9.
5. Bergamaschi A, Kim YH, Wang P, Srlie T, Hernandez-Boussard T, Lonning PE, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Gene Chromosome Cancer 2006;45:1033-40.
6. Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 2004;64:64-71.
7. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23.
8. Bryant HE, Helleday T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res 2006;34:1685-91.
9. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
10. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
11. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15.
12. Yap T. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I; 2007;25:18S (June 20 Supplement):3529.
13. Ganguly A, Rock MJ, Prockop DJ. Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci USA 1993;90:10325-9.
14. Korkko J, Milunsky J, Prockop DJ, Ala-Kokko L. Use of conformation sensitive gel electrophoresis to detect single-base changes in the gene for COL10A1. Hum Mutat 1998;Suppl 1:S201-3.
15. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev 2003;3:23-34.
16. Moldovan GL, D'Andrea AD. How the Fanconi anemia pathway guards the genome. Annu Rev Genet 2009;43:223-49
17. Shimamura A, Montes de Oca R, Svenson JL, Haining N, Moreau LA, Nathan DG, et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 2002;100:4649-54.
18. Sijbers AM, de Laat WL, Ariza RR, Biggerstaff M, Wei YF, Moggs JG, et al. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell 1996;86:811-22.
19. Bhagwat N, Olsen AL, Wang AT, et al. XPF-ERCC1 participates in the Fanconi anemia pathway of crosslink repair. Mol Cell Biol 2009;29:6427-37.
20. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 2000;20:7980-90.
21. Hoy CA, Thompson LH, Mooney CL, Salazar EP. Defective DNA cross-link removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents. Cancer Res 1985;45:1737-43.
22. Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E, et al. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 2006;444:1038-43.
23. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
24. Kennedy RD, D'Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006;24:3799-808.
25. Manke IA, Nguyen A, Lim D, Stewart MQ, Elia AEH, Yaffe MB. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 2005;17:37-48.
26. Kerfoot C, Huang W, Rotenberg SA. Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase C alpha. J Histochem Cytochem 2004;52:419-22.
27. Meng W, Swenson LL, Fitzgibbon MJ, Hayakawa K, Ter Haar E, Behrens AE, et al. Structure of mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase activation with nuclear export. J Biol Chem 2002;277:37401-5.
28. Li Y, Dong M, Kothari R. Classifiability-based omnivariate decision trees. IEEE Trans Neural Netw 2005;16:1547-60.
29. Eisen JA, Hanawalt PC. A phylogenomic study of DNA repair genes, proteins, and processes. Mutat Res 1999;435:171-213.
30. Friedberg EC. DNA damage and repair. Nature 2003;421:436-40.
31. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009;361:1475-85.
32. Cohn MA, D'Andrea AD. Chromatin recruitment of DNA repair proteins: lessons from the Fanconi anemia and double-strand break repair pathways. Mol Cell 2008;32:306-12.
33. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA 2003;100:776-81.
34. Loeb LA, Bielas JH, Beckman RA. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res 2008;68:3551-7; discussion 7.
35. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 2005;31:603-17.
36. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91.
37. Adélaïde J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, et al. Integrated profiling of basal and luminal breast cancers. Cancer Res 2007;67:11565-75.
38. Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009;15:441-51.
39. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-41.
40. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001;2:483-90.
41. Kennedy RD, D'Andrea AD. The Fanconi anemia/BRCA pathway: new faces in the crowd. Genes Dev 2005;19:2925-40.
42. Timmers C, Taniguchi T, Hejna J, Reifsteck C, Lucas L, Bruun D, et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell 2001;7:241-8.
43. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001;7:249-62.
44. Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2008;115:359-63.
45. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-9.
46. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008;451:1111-5.
47. Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 2009;69:6381-6.
48. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451:1116-20.
49. Albertella MR, Green CM, Lehmann AR, O'Connor MJ. A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. Cancer Res 2005;65:9799-806.
50. Tassone P, Di Martino MT, Ventura M, et al. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 2009;8:648-53.
51. Sgagias MK, Wagner KU, Hamik B, Stoeger S, Spieker R, Huber LJ, et al. Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS. Cell Cycle 2004;3:1451-6.
52. Clingen PH, Arlett CF, Hartley JA, Parris CN. Chemosensitivity of primary human fibroblasts with defective unhooking of DNA interstrand cross-links. Exp Cell Res 2007;313:753-60.
53. Bulmer JT, Zacal NJ, Rainbow AJ. Human cells deficient in transcription-coupled repair show prolonged activation of the Jun N-terminal kinase and increased sensitivity following cisplatin treatment. Cancer Chemother Pharmacol 2005;56:189-98.
54. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 2009;27: 18s (suppl.; abstr3).
55. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet; 376:245-51.
56. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet; 376:235-44.